by nikki mann | Jul 16, 2026 | News
We are delighted to announce that we have joined the o2h Discovery Platinum Partner Programme, enabling eligible companies within our bio-incubator and wider affiliate network to access specialist drug discovery support through the o2h Kickstarter Award. As part of...
by nikki mann | Jul 9, 2026 | News
Researchers, entrepreneurs, investors and global pharmaceutical leaders gathered in Cambridge this week as the Milner Therapeutics Institute hosted its annual Pitch Day and 11th annual Therapeutics Symposium. Held over two consecutive days, these flagship events...
by nikki mann | Jul 3, 2026 | News
A key goal of the Milner from the outset has been to drive new models for academic-industry collaborations, and to lower barriers to engagement across these sectors. While the Milner Therapeutics Consortium is rooted in the Cambridge ecosystem – providing a hub for...
by nikki mann | May 18, 2026 | News
Cambridge’s biotech ecosystem is built on progression – from early discovery through to scale. As TRIMTECH expands out of the Milner Therapeutics Institute’s Bio-incubator and into the Babraham Research Campus, we are pleased to reflect on their journey so far. ...
by nikki mann | Apr 23, 2026 | News
Last week, we joined forces with Cambridge Enterprise to welcome Curie.Bio to Cambridge – a venture capital firm that helps founders discover and develop important new medicines. We began the day by welcoming Curie.Bio leadership at the Milner Therapeutics Institute...
by nikki mann | Mar 26, 2026 | News
We’re delighted that Milner Institute Bio-incubator company Immutrin has announced the successful close of a £65 million ($87 million) Series A financing round to develop a next-generation antibody therapy for ATTR amyloidosis. This funding will enable Immutrin to...
